Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Dr Shah Discusses HER-RAM Study Results in HER2+ GI Cancers

Manish Shah, MD, highlights the multi-center, phase 1b/2 study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer (HER-RAM study), presented at the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. 

Advertisement

Advertisement

Advertisement

Advertisement